Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Recruiting · NCT07375225 · Observational (researchers observe without assigning treatment) · Lead sponsor: Federico II University
View the official record on ClinicalTrials.gov →Interventions studied
Praluent (Alirocumab)
What this trial is about
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- \- Patients under alirocumab 300mg treatment.
Exclusion criteria
- Age \< 18 years o \> 80 years;
- Patients who refuse to participate and to sign informed consent.
Where it is running
1 location listed.
- Federico II University of Naples, Department of Advanced Biomedical Sciences - Naples, Napoli, Italy